Breaking News
Get 55% Off 0
🎈 Up Big Today: Find today's biggest gainers with our free screener
Try Stock Screener
Close

Teva Pharma Industries Ltd ADR (TEVA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Teva ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.81 -0.64    -3.67%
15:59:59 - Closed. Currency in USD
After Hours
16.90
+0.09
+0.54%
17:29:30 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 6,497,761
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.79 - 17.72
Teva ADR 16.81 -0.64 -3.67%

Teva Pharma Industries Ltd ADR Company Profile

 
Get an in-depth profile of Teva Pharma Industries Ltd ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

35737

Equity Type

ADR

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Contact Information

Address 124 Dvora HaNevi’a Street
Tel Aviv, 6944020
Israel
Phone 972 3 914 8213
Fax 972 3 923 4050

Top Executives

Name Age Since Title
Sol J. Barer 75 2015 Independent Chairman of the Board
Amir Elstein 67 2005 Independent Director
Roberto Agostino Mignone 51 2017 Independent Director
Rosemary A. Crane 63 2015 Independent Director
Gerald M. Lieberman 76 2015 Independent Director
Tal Zaks 57 2021 Independent Director
Perry D. Nisen 67 2017 Independent Director
Ronit Satchi-Fainaro 51 2018 Independent Director
Varda Shalev 63 2023 Independent Director
Richard D. Francis 56 2023 President, CEO & Director
Chen Lichtenstein 57 2024 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Comments

Write your thoughts about Teva Pharma Industries Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni Dec 05, 2024 6:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
TSahi Livnoni
TSahi Livnoni Sep 05, 2024 8:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New price target of 26$ the other day
TSahi Livnoni
TSahi Livnoni Aug 15, 2024 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Price targets and ER delayed response, now 18.5$
TSahi Livnoni
TSahi Livnoni Jun 27, 2024 8:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Glen Santangelo from Jefferies, Buy, 23$
TSahi Livnoni
TSahi Livnoni Jun 14, 2024 5:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All new price targets are buy and above 20$-21$
TSahi Livnoni
TSahi Livnoni May 09, 2024 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
One day to ER of Q1
TSahi Livnoni
TSahi Livnoni May 07, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New price target of 17$ by Barclays analyst
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email